Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK4 | P11802 | 16/20 | 1.00 |
| ▸ | CCND1 | P24385 | 16/20 | 1.00 |
| ▸ | CCNE2 | O96020 | 9/20 | 1.00 |
| ▸ | CCNE1 | P24864 | 9/20 | 1.00 |
| ▸ | CDK2 | P24941 | 9/20 | 1.00 |
| ▸ | CAMK2B | Q13554 | 9/20 | 1.00 |
| ▸ | CAMK2G | Q13555 | 9/20 | 1.00 |
| ▸ | CAMK2D | Q13557 | 9/20 | 1.00 |
| ▸ | CAMK2A | Q9UQM7 | 9/20 | 1.00 |
| ▸ | CCNB2 | O95067 | 5/20 | 1.00 |
| ▸ | CDK1 | P06493 | 5/20 | 1.00 |
| ▸ | CCNB1 | P14635 | 5/20 | 1.00 |
| ▸ | CCNB3 | Q8WWL7 | 5/20 | 1.00 |
| ▸ | CDK5 | Q00535 | 3/20 | 1.00 |
| ▸ | CDK5R1 | Q15078 | 3/20 | 1.00 |
| ▸ | CCNA2 | P20248 | 2/20 | 1.00 |
| ▸ | CCNT1 | O60563 | 1/20 | 1.00 |
| ▸ | EIF2AK2 | P19525 | 1/20 | 1.00 |
| ▸ | CDK9 | P50750 | 1/20 | 1.00 |
| ▸ | PRKACA | P17612 | 2/20 | 0.74 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22566990 | 0.93 | CDK4 (0.86) | CDK4CCND1CCNE2CCNE1CDK2 | |
| Staurosporine Aglycon SCHEMBL8124103 | 0.86 | CDK4 (1.00) | CDK4CCND1CCNE2CCNE1CDK2 | |
| Staurosporine Aglycon SCHEMBL30530825 | 0.86 | CDK4 (1.00) | CDK4CCND1CCNE2CCNE1CDK2 | |
| Staurosporine Aglycon SCHEMBL29406635 | 0.86 | CDK4 (1.00) | CDK4CCND1CCNE2CCNE1CDK2 | |
| SCHEMBL8127691 | 0.84 | CDK4 (1.00) | CDK4CCND1CCNE2CCNE1CDK2 | |
| SCHEMBL8127688 | 0.83 | CDK4 (0.86) | CDK4CCND1CCNE2CCNE1CDK2 | |
| SCHEMBL29511391 | 0.80 | GLI1 (1.00) | CDK4CCND1CCNE2CCNE1CDK2 | |
| SCHEMBL6632580 | 0.78 | CDK4 (0.63) | CDK4CCND1CCNE2CCNE1CDK2 | |
| SCHEMBL6631769 | 0.78 | CDK4 (0.63) | CDK4CCND1CCNE2CCNE1CDK2 | |
| SCHEMBL14708731 | 0.77 | CDK4 (0.80) | CDK4CCND1CCNE2CCNE1CDK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 60 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3463342-B1 | ESTROGEN RECEPTOR MODULATOR COMBINATIONS | UNIV CALIFORNIA (US) | 2023-09-06 | — | — | EP | claimed |
| US-20210275657-A1 | NEOANTIGENS AND USES THEREOF | NEON THERAPEUTICS, INC. | 2021-09-09 | — | — | US | claimed |
| EP-3810180-A1 | NEOANTIGENS AND USES THEREOF | BioNTech US Inc. (US) | 2021-04-28 | — | — | EP | claimed |
| CN-112584852-A | Novel antigens and uses thereof | 百欧恩泰美国公司 | 2021-03-30 | — | — | CN | claimed |
| US-10421948-B2 | Methods for making pancreatic endocrine cells | JANSSEN BIOTECH, INC. (US) | 2019-09-24 | — | — | US | claimed |
| EP-3344275-A1 | PEPTIDOMIMETIC MACROCYCLES AND USES THEREOF | Aileron Therapeutics, Inc. (US) | 2018-07-11 | — | — | EP | claimed |
| US-20170355963-A1 | DIFFERENTIATION OF HUMAN PLURIPOTENT STEM CELLS | JANSSEN BIOTECH, INC. (US) | 2017-12-14 | — | — | US | claimed |
| US-9752126-B2 | Differentiation of human pluripotent stem cells | JANSSEN BIOTECH, INC. (US) | 2017-09-05 | — | — | US | claimed |
| EP-2346988-B1 | DIFFERENTIATION OF HUMAN EMBRYONIC STEM CELLS TO THE PANCREATIC ENDOCRINE LINEAGE | JANSSEN BIOTECH INC (US) | 2017-05-31 | — | — | EP | claimed |
| WO-2017040990-A1 | PEPTIDOMIMETIC MACROCYCLES AND USES THEREOF | AILERON THERAPEUTICS, INC. (US) | 2017-03-09 | — | — | WO | claimed |
| US-20160160182-A1 | Differentiation of Human Pluripotent Stem Cells | JANSSEN BIOTECH, INC. (US) | 2016-06-09 | — | — | US | claimed |
| WO-2013071415-A1 | TARGETING THE RB PATHWAY FOR THE PREVENTION OF CANCER | UNIVERSITY HEALTH NETWORK (CA) | 2013-05-23 | — | — | WO | claimed |
| EP-3344275-B1 | PEPTIDOMIMETIC MACROCYCLES AND USES THEREOF | AILERON THERAPEUTICS INC (US) | 2023-03-08 | — | — | EP | disclosed |
| US-20230037284-A9 | COMBINATION THERAPY OF PEPTIDOMIMETIC MACROCYCLES | AILERON THERAPEUTICS, INC. | 2023-02-02 | — | — | US | disclosed |
| US-11318138-B2 | Methods for treating B cell proliferative disorders | CORNELL UNIVERSITY (US) | 2022-05-03 | — | — | US | disclosed |
| US-20210363189-A1 | COMBINATION THERAPY OF PEPTIDOMIMETIC MACROCYCLES | AILERON THERAPEUTICS INC (US) | 2021-11-25 | — | — | US | disclosed |
| US-20100112693-A1 | Differentiation of Human Embryonic Stem Cells | CENTOCOR ORTHO BIOTECH, INC. | 2010-05-06 | — | — | US | disclosed |
| WO-2010048273-A2 | METHODS AND COMPOUNDS FOR TREATMENT OF NEURODEGENERATIVE DISORDERS | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2010-04-29 | — | — | WO | disclosed |
| WO-2010039997-A2 | HEMATOPOIETIC PROTECTION AGAINST CHEMOTHERAPEUTIC COMPOUNDS USING SELECTIVE CYCLIN-DEPENDENT KINASE 4/6 INHIBITORS | THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL (US) | 2010-04-08 | — | — | WO | disclosed |
| US-20080044390-A1 | Methods and compositions for the treatment of neurodegenerative disorders | CHDI, INCORPORATED | 2008-02-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11318138-B2 | Methods for treating B cell proliferative disorders | CDK4, BCL6, BCL6B | CDK4 1/4885CCND1 50/4885CCNE2 141/4885 |
| US-20230037284-A9 | COMBINATION THERAPY OF PEPTIDOMIMETIC MACROCYCLES | BID, FLT3, GRPR | CDK4 175/4885CCND1 2634/4885CCNE2 3047/4885 |
| US-20080044390-A1 | Methods and compositions for the treatment of neurodegenerative disorders | HTT, SNCA, NLN | CDK4 3176/4885CCND1 4863/4885CCNE2 4764/4885 |
| US-20210363189-A1 | COMBINATION THERAPY OF PEPTIDOMIMETIC MACROCYCLES | BID, FLT3, GRPR | CDK4 175/4885CCND1 2634/4885CCNE2 3047/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.